This content is machine translated Type 2 diabetes SGLT-2 inhibitors: a new oral therapy option Dapagliflozin, a potent new selective SGLT-2 inhibitor, is available in many countries for use in type 2 diabetes patients either as add-on combination therapy when other glucose-lowering medical agents together…
